HOME >> BIOLOGY >> NEWS
Evidence Mounts Against Maintstream Dogma In Embryology, Could Shed New Light On,,Neurological Defects

New work on zebrafish development is about to complicate a debate already brewing among embryologists. According to the mainstream dogma, the notochord, a rod-like structure that precedes the vertebral column in vertebrate embryos, signals neural cells to induce the formation of floor plate, a crucial row of cells that lies along the floor of the ventral brain and spinal cord. This belief has come under fire recently, as new data about floor plate development cast doubt on the authoritative role of the notochord.

A group of scientists at the Carnegie Institution of Washington, Vanderbilt University, and the National University of Singapore bring forth more evidence in opposition to the classic model with their report appearing in the September 10 Nature. The authors argue that the first steps in floor plate development occur earlier than was initially thought, in reaction to inducing factors other than those emitted by the notochord. The new data, based on studies of zebrafish mutants, may also shed light on certain neurological defects that affect humans as well as fish namely, holoprosencephaly. This syndrome, which can result in severe deformity and death, prevents the forebrain hemispheres from separating normally, in turn preventing the initial eye field from separating into two eyes during embryonic development.

The model

The mainstream model for patterning of the central nervous system was demonstrated in the 1980s and much supportive evidence has been obtained ever since. In this model, the notochord instructs neural tube precursor cells to differentiate into floor plate during the early stages of somitogenesis (i.e., the time of formation of somites, blocks of similar cells that differentiate into muscles, bone, and other tissues). The command arrives via a potent messenger protein, Sonic hedgehog. Once formed, the floor plate then induces motor neurons to develop on either side (motor neurons will ultimately relay
'"/>

Contact: Catherine Whittenburg
cwhittenburg@pst.ciw.edu
(202) 939-1121
Carnegie Institution
9-Sep-1998


Page: 1 2 3

Related biology news :

1. Evidence builds for potential new cancer drug target
2. Evidence for sympatric speciation by host shift in the sea
3. Evidence for the impact of climate change on deep-sea biodiversity
4. Evidence for fat hormone target in brain
5. Evidence of nanobacterial-like structures found in human calcified arteries and cardiac valves
6. Evidence shows the heart has stem cells able to regenerate muscle tissue lost to disease, wear
7. Evidence for orangutan culture
8. Evidence suggests that standard smallpox vaccine offers long-term immunity
9. Evidence that adults stem cells differentiate like embryonic stem cells published in Nature
10. When Shewanella meets goethite: Evidence found of recognition between animate and inanimate objects
11. Evidence links protein damage to Parkinsons

Post Your Comments:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: